Imaging features of breast infiltrating ductal carcinoma

Triple-negative invasive ductal carcinoma (TNIDC) is a subtype of breast cancer that lacks expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). This aggressive form of cancer accounts for approximately 10-20% of all breast cancers and is associated with a poor prognosis due to its high recurrence rate and limited treatment options. The present case report highlights a clinical presentation of a 46-year-old female diagnosed with TNIDC of the breast. She presented with a palpable mass in her right breast, and diagnostic imaging and biopsy confirmed the presence of invasive ductal carcinoma with triple-negative characteristics. The case plan of management was neoadjuvant chemotherapy. Pathologic examination confirmed the tumor's triple-negative status. The report emphasizes the importance of early diagnosis, genetic testing, and personalized therapeutic strategies, as well as the challenges in treating TNIDC due to its aggressive nature and resistance to hormonal therapies. This case underscores the need for continuous research into novel therapeutic agents, including immunotherapy and targeted treatments, to improve outcomes for patients with triple-negative breast cancer. Further investigation into biomarkers and potential targeted therapies could pave the way for more effective treatment regimens for this challenging disease.